Biomedikal Llc

Biomedikal Llc is a pharmaceutical importer based in Uzbekistan, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Uzbek pharmaceutical distribution network, ensuring the availability of essential medications across the country. While specific details about its headquarters and parent company are not publicly disclosed, Biomedikal Llc's operations are integral to the nation's healthcare supply chain.

Biomedikal Llc's distribution network encompasses multiple warehouse locations strategically situated to facilitate efficient logistics and timely delivery of pharmaceutical products throughout Uzbekistan. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of imported medications. While the exact geographic coverage within Uzbekistan is not specified, Biomedikal Llc's operations are designed to meet the pharmaceutical needs of the entire nation.

In Uzbekistan's pharmaceutical supply chain, Biomedikal Llc functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers, notably from India. The company is not identified as a primary wholesaler, parallel importer, hospital supplier, or logistics intermediary, but rather focuses on the importation of finished pharmaceutical products to meet domestic demand.

Biomedikal Llc exhibits a high degree of supplier concentration, with its imports predominantly sourced from three Indian suppliers:

• COMBITIC GLOBAL CAPLET PRIVATE LIMITED: $2.9 million (67.3% of total imports)
• GOD GIFT LABORATORY PRIVATE LIMITED: $1.4 million (32.3% of total imports)
• SWISS HEALTHCARE: $19,000 (0.4% of total imports)

This concentration suggests a strategic choice to maintain strong, stable relationships with key suppliers, potentially ensuring consistent product quality and supply reliability. However, such dependency also poses risks, including vulnerability to supply chain disruptions or changes in supplier dynamics.

Biomedikal Llc's supply chain resilience is influenced by its reliance on a limited number of suppliers. The company's focus on finished pharmaceutical formulations from India indicates a streamlined procurement strategy. While this approach may enhance efficiency, it also exposes the company to risks associated with geopolitical tensions, regulatory changes, or logistical challenges affecting its Indian suppliers. The lack of publicly available information on backup suppliers and formulation diversity suggests potential areas for strengthening supply chain resilience.

Biomedikal Llc's sourcing pattern, characterized by a concentrated supplier base, positions the company to leverage strong supplier relationships and potentially negotiate favorable terms. For Indian exporters, this presents an opportunity to deepen partnerships with Biomedikal Llc, offering a pathway to expand their market presence in Uzbekistan. However, the concentration also implies that any disruptions with these key suppliers could significantly impact Biomedikal Llc's operations, highlighting the importance of maintaining robust and diversified supplier relationships.

The pharmaceutical industry in Uzbekistan is regulated by the Ministry of Health, which oversees the registration, certification, and importation of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Law on Medicines and Pharmaceutical Activities, which outlines the procedures for state registration and quality control of medicines. The marketing authorization pathway for Indian generics involves obtaining state registration from the Ministry of Health, ensuring compliance with Uzbekistan's regulatory standards.

Import licensing requirements in Uzbekistan stipulate that pharmaceutical importers must hold a wholesale distribution license issued by the Ministry of Health. Additionally, imported pharmaceutical products must be accompanied by a Good Manufacturing Practice (GMP) certificate recognized by Uzbekistan's regulatory authorities. Uzbekistan acknowledges GMP certifications from various international standards, including EU GMP, WHO GMP, and PIC/S, facilitating the importation of quality-assured medicines.

Imported pharmaceutical products are subject to mandatory certification by accredited bodies in Uzbekistan. Labeling requirements include providing instructions for use in the Uzbek language, ensuring that consumers have access to essential information in their native language. Serialization mandates, such as the National Digital Labeling System "Asl Belgisi," are implemented to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Uzbekistan introduced several regulatory changes affecting pharmaceutical imports:

• January 2025: A presidential decree imposed a 2% customs duty on the import of certain medicines, including antibiotics, painkillers, and antiviral medications, to support the development of the domestic pharmaceutical industry. (kun.uz)

• November 2025: The government simplified import procedures for certified medicines, aligning the pharmaceutical system with global standards and facilitating the entry of foreign products. (kun.uz)

Biomedikal Llc's focus on importing pharmaceutical products across three therapeutic categories—Gastrointestinal (48.8%), Antihistamines & Allergy (38.3%), and Antimalarial & Antiparasitic (12.9%)—indicates a strategic alignment with prevalent health concerns in Uzbekistan. The substantial importation of ranitidine and chlorpheniramine suggests a response to significant demand in gastrointestinal and allergy treatments, respectively. The inclusion of levamisole reflects a commitment to addressing parasitic infections, which remain a public health priority.

Biomedikal Llc's sourcing strategy emphasizes the importation of generic drugs, primarily from India, known for its robust pharmaceutical manufacturing sector. The company's preference for finished pharmaceutical formulations aligns with its goal to provide ready-to-use medications to the Uzbek market. This approach ensures a consistent supply of essential medicines, catering to the therapeutic needs of the population.

Based on its product mix, Biomedikal Llc serves a broad segment of the Uzbekistan market, including retail pharmacies, hospitals, and government tenders. The company's importation of widely used medications positions it as a key supplier in the pharmaceutical distribution network, contributing to the accessibility and affordability of essential medicines across the country.

There is a realistic opportunity for new Indian suppliers to engage with Biomedikal Llc, given the company's established sourcing patterns and the demand for diverse pharmaceutical products in Uzbekistan. Potential gaps in Biomedikal Llc's current sourcing include the need for additional suppliers to mitigate risks associated with supplier concentration and to enhance supply chain resilience.

Indian exporters seeking to supply Biomedikal Llc and the Uzbekistan market must ensure compliance with Uzbekistan's regulatory requirements, including obtaining GMP certifications recognized by the Ministry of Health. Products must undergo state registration, and labeling must meet the standards set by Uzbek authorities, including instructions in the Uzbek language. Adherence to serialization mandates is also essential to facilitate market entry.

To establish a relationship with Biomedikal Llc, Indian exporters should initiate contact to understand the company's specific product requirements and quality standards. Participating in tenders and responding to requests for proposals can provide opportunities to supply products. Developing a comprehensive regulatory filing strategy, including obtaining necessary certifications and ensuring compliance with labeling and serialization requirements, is crucial. Timelines for regulatory approvals can vary, so proactive engagement with Uzbek authorities is recommended to expedite the process.